SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.
| Κύριος συγγραφέας: | |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Thesis |
| Γλώσσα: | English |
| Έκδοση: |
Brac University
2023
|
| Θέματα: | |
| Διαθέσιμο Online: | http://hdl.handle.net/10361/18081 |
| id |
10361-18081 |
|---|---|
| record_format |
dspace |
| spelling |
10361-180812023-04-05T21:01:45Z SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy Meem, Manila Akter, Dr. Raushanara Department of Pharmacy, Brac University Cancer SHP2 inhibitors Targeted therapy Catalytic inhibitor Allosteric inhibitor. Cancer research. This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. Cataloged from PDF version of thesis. Includes bibliographical references (pages 45-51). SHP2 (Src homology-2 domain-containing protein tyrosinephosphatase-2) works as a tyrosine phosphatase, to eliminate tyrosine phosphorylation in the non-receptor protein to link many oncogenic signaling pathways including RAS/RAF/MAPK and PI3K/AKT. Mutations and overexpression in SHP2 cause cancer and related abnormalities in the body including leukemia or solid tumors. Hence, SHP2 has piqued the interest of researchers as a target for inhibition. Several therapeutic compounds are undergoing clinical trials where SHP2 undergoes conformational modifications by binding either inside or outside the catalytic pocket of PTP. These compounds impact different types of cancer with varying efficiencies indicating their excellent chemotherapeutic potential. Therefore, this review has explored the function and structure of SHP2, its relationship with cancer, and strategies to target its catalytic pocket and allosteric regions as an effective cancer treatment option. Additionally, an insight into these compounds’ prospects has portrayed their advancements and limitations in cancer treatment through modulation of SHP2. Manila Meem B. Pharmacy 2023-04-05T04:17:38Z 2023-04-05T04:17:38Z 2022 2022-03 Thesis ID: 18146062 http://hdl.handle.net/10361/18081 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 51 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Cancer SHP2 inhibitors Targeted therapy Catalytic inhibitor Allosteric inhibitor. Cancer research. |
| spellingShingle |
Cancer SHP2 inhibitors Targeted therapy Catalytic inhibitor Allosteric inhibitor. Cancer research. Meem, Manila SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. |
| author2 |
Akter, Dr. Raushanara |
| author_facet |
Akter, Dr. Raushanara Meem, Manila |
| format |
Thesis |
| author |
Meem, Manila |
| author_sort |
Meem, Manila |
| title |
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy |
| title_short |
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy |
| title_full |
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy |
| title_fullStr |
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy |
| title_full_unstemmed |
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy |
| title_sort |
shp2 inhibitors: recent advancements and potential breakthroughs in cancer therapy |
| publisher |
Brac University |
| publishDate |
2023 |
| url |
http://hdl.handle.net/10361/18081 |
| work_keys_str_mv |
AT meemmanila shp2inhibitorsrecentadvancementsandpotentialbreakthroughsincancertherapy |
| _version_ |
1814309212643131392 |